Grants and Contributions:
Title:
Critical Technology Transfer Activities to Enable Timely and Cost Effective AAV Biomanufacturing at the BMC- Part II
Agreement Number:
1023387
Agreement Value:
$887,131.00
Agreement Date:
Dec 12, 2024 - Mar 31, 2026
Description:
The Project will accelerate the rate at which the NRC’s Lipoprotein lipase deficiency (LPLD) AAV-based gene therapy technology is GMP manufactured and readied for testing in the clinic, by formally combining the efforts, experience and expertise of the National Research Council and the Biotherapeutics Manufacturing Centre- Virus Manufacturing Facility (BMC-VMF) at the Ottawa Hospital Research Institute (OHRI). The project will result in the finalization of upstream and downstream process parameters leading to the execution of a non-GMP run of the complete, finalized process. Importantly, this non-GMP run will generate material that is suitable and required for a pivotal GLP toxicology study while serving to validate the feasibility of the overall process (at reduced scale) at the BMC
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Ottawa, Ontario, CA K1H 8L6
Reference Number:
172-2024-2025-Q3-1023387
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
886822212
Recipient Type:
Not-for-profit organization or charity
Recipient's Legal Name:
Ottawa Hospital Research Institute
Federal Riding Name:
Ottawa South
Federal Riding Number:
35080
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
NAICS Code:
541710